A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood by unknown
Watanabe et al. Journal of Translational Medicine 2014, 12:143
http://www.translational-medicine.com/content/12/1/143METHODOLOGY Open AccessA novel flow cytometry-based cell capture platform
for the detection, capture and molecular
characterization of rare tumor cells in blood
Masaru Watanabe1,2, Masakuni Serizawa1, Takeshi Sawada3, Kazuo Takeda4, Toshiaki Takahashi5, Nobuyuki Yamamoto2,5,
Fumiaki Koizumi3 and Yasuhiro Koh1,2*Abstract
Background: Personalized cancer treatment relies on the accurate detection of actionable genomic aberrations in
tumor cells. Circulating tumor cells (CTCs) could provide an alternative genetic resource for diagnosis; however, the
technical difficulties in isolating and analyzing rare CTCs have limited progress to date. In this preclinical study, we
aimed to develop an improved capture system for molecular characterization of CTCs based on a novel cell sorting
technology.
Methods: We developed a cell capture platform using On-chip Sort (On-Chip Biotechnologies), a novel bench-top
cell sorter equipped with a disposable microfluidic chip. Spike-in experiments comprising a series of lung cancer cell
lines with varying epithelial cell adhesion molecule (EpCAM) expression levels were conducted to assess the capture
and purification efficiency of the platform. Samples were negatively enriched using anti-CD45-coated magnetic beads
to remove white blood cells, followed by sample fixation and labeling. The enriched and labeled samples were then
sorted by On-chip Sort based on cytokeratin, vimentin, and CD45 expression. Captured cells were immediately
subjected to whole genome amplification followed by mutation analysis using deep targeted sequencing, and
copy number analysis using quantitative polymerase chain reaction (qPCR).
Results: Spike-in experiments revealed an excellent overall mean capture rate of 70.9%. A 100% success rate in the
detection of EGFR, KRAS and BRAF mutations from captured cells was achieved using pyrosequencing and deep
sequencing. The mutant variant detection rates were markedly higher than those obtained with the CellSearch
profile kit. qPCR analysis of amplified DNA demonstrated reproducible detection of copy number changes of the
EGFR in captured tumor cells.
Conclusions: Using a novel cell sorter, we established an efficient and convenient platform for the capture of
CTCs. Results of a proof-of-principle preclinical study indicated that this platform has potential for the molecular
characterization of captured CTCs from patients.
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Recent advances in molecularly targeted cancer therapy
have offered up a wide variety of therapeutic strategies.
The presence or absence of various actionable genomic
aberrations has been shown to predict response to molecu-
larly targeted treatments [1]. In some cases, identification
of genetic aberrations is a prerequisite for commencing
treatment; for example, identification of EGFR-activating
mutations in patients with non-small cell lung cancer is
required prior to starting treatments with EGFR tyrosine
kinase inhibitors [2]. However, kinase inhibition frequently
leads to the appearance of drug resistance mutations
within the target kinase itself, such as the EGFR T790M
mutation [3].
In addition to identifying gene mutations, there is also
a need for detection of protein expression and gene
amplification of targeted molecules on primary tumor
cells for further stratification of patients [4]. To optimize
treatment, real-time monitoring of tumors over the course
of the treatment, especially at the point of treatment fail-
ure, is necessary. However, rebiopsy remains challenging,
mainly because of the invasiveness of the procedure.
Circulating tumor cells (CTCs) could potentially serve
as an alternative to tumor tissue as a source of material
for the detection of genetic alterations, an approach that
is termed “liquid biopsy” [5-11] owing to its minimal inva-
siveness. To date, the CellSearch system (Veridex LLC,
Raritan, NJ, USA) is the only United States Food and Drug
Administration-approved CTC enumeration system for
the provision of prognostic information regarding survival
[12-17]. However, the isolation of the rare CTCs for
molecular analysis remains technically challenging. Most
of the currently available capture methods retain a
considerable number of white blood cells (WBCs) and
cell loss during sample handling. Various methods to
overcome this issue have been under development and
evaluation [18-28].
The conventional cell sorting device is a well-established
cell capture system and it has previously been used to
enrich CTCs from whole blood [29]. However, it is report-
edly difficult to efficiently carry out this isolation when
using blood samples with a low CTC count together with
a conventional fluorescence-activated cell sorter [20].
Recently, we have established a protocol for CTCs
enumeration using a newly-developed flow cytometry
FISHMAN-R [30]. The results of preclinical study showed
superior sensitivity of their system in detecting EpCAM-
negative tumor cells in direct comparison with the
standard method. This protocol also enables a detection
of EpCAM−/CK− cells and epithelial-mesenchymal transi-
tion (EMT)-induced tumor cells using the incorporation
of an EMT marker [30]. The system and protocol have
been evaluated and validated for the enumeration of CTCs
in clinical feasibility study [31,32].In this study, we introduced a new approach for the
characterization of CTCs captured by On-chip Sort cell
sorter. This novel cell sorter is an integrated sorting unit
with FISHMAN-R, allowing the detection and isolation
of rare tumor cells for subsequent molecular analyses.
Here we evaluate the feasibility of mutation analysis of
the isolated rare cell in blood after immunomagnetic
enrichment and fluorescence-activated cell sorting. This
is an efficient and convenient platform based on a cell
sorting system, and promising preclinical results were
obtained for possible future clinical application.
Methods
Cell lines and culture
The tumor cell lines A431, A549, H292, HCC827, H1975,
and H1755 were obtained from the American Type
Culture Collection (ATCC; Lockville, MD). The breast
cancer cell line Hs578T was kindly gifted by Dr. Tohru
Mochizuki (Shizuoka Cancer Center Research Institute,
Japan). A549, H292, HCC827, H1975, and H1755 cells were
cultured in RPMI-1640 (Invitrogen, Carlsbad, CA) contain-
ing 10% fetal bovine serum (Gibco, Life Technologies,
Grand Island, NY). A431 and Hs578T cells was cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen)
containing 10% FBS. Cell lines were cultured under
humidified 5% CO2/95% air at 37°C.
Blood spiking experiments
Blood samples of 4 mL each were spiked with 5–25 cells of
the above-mentioned cell lines and were used for the isola-
tion of tumor cells for mutation and gene copy number
analysis. Blood samples were collected from healthy volun-
teers working at Shizuoka Cancer Center who consented to
donation. This study was approved by the independent
institutional review board of Shizuoka Cancer Center.
Tumor cells were harvested by incubation with 0.25%
trypsin/EDTA (Gibco) solution for several minutes at 37°C,
and then washed and resuspended in T-buffer {0.5% bovine
serum albumin (Nacalai Tesque Inc., Kyoto, Japan) and
2 mM ethylenediaminetetraacetic acid (EDTA; Sigma-
Aldrich, St. Louis, MO), and 0.5% Through Path Plus
(On-Chip Biotechnologies, Tokyo, Japan) in phosphate-
buffered saline (PBS, Invitrogen)} to obtain a final concen-
tration of 102 cells/100 μL. From this suspension, tumor
cells were individually picked up using a micropipette
under an inverted microscope, and subsequently added to
the 4 mL healthy blood sample. These spiked samples
were then processed immediately via immunomagnetic
enrichment as described below.
Immunomagnetic enrichment and sample staining
procedures
Immunomagnetic enrichment and sample staining of
cells were described previously [30]. Briefly, samples
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anti-CD45 monoclonal antibody (Invitrogen) to remove
white blood cells, followed by fixation and labeling
with the fluorescein isothiocyanate (FITC)-conjugated
anti-CK mAb CK3-6H5 (1:25 dilution; Miltenyi Biotec,
Bergisch-Gladbach, Germany), the PE-conjugated anti-
vimentin mAb D21H3 (1:50 dilution; Cell Signaling
Technology, Danvers, MA), and the Alexa Fluor 700-
conjugated anti-CD45 mAb F10-89-4 (1:20 dilution; AbD
Serotec, Oxford, UK). Samples were incubated overnight
at 4°C in the dark, followed by stained with 1 μg/mL
Hoechst 33342 (Sigma-Aldrich, St. Louis, MO) for 10 min
at RT in the dark.
On-chip Sort cell sorter
The novel cell sorter used in this study, On-chip Sort
(On-Chip Biotechnologies, Tokyo, Japan), is a bench-top
size sorter that is compatible with operation in most bio-
safety cabinets (Figure 1A). As shown in Figure 1B, the
disposable microfluidic chip contains all fluidic and optical
paths within a single, closed system, which is intended to
realize cross contamination-free, biosafety adherent, lossless
whole volume sorting. This system therefore provides suit-
able conditions for the capture of CTCs in a clinical setting.
The principle of sorting will be described elsewhere.
The On-chip Sort of this paper has two excitation lasers






























Figure 1 Cell sorter instrument and gating mechanism for tumor cell
microfluidic chip used. The chip is self-contained with both inlet and outle
contact with the device. The target cells are separated to the collection reserv
is shown in the inset on the right. (C) Sorting gates for spiked tumor cells. Tu
Nuclei, cytokeratin, vimentin and CD45 staining was used to distinguish tumo
white blood cell population (White blood cell, WBC; nuclei+/CK−/vimentin+/Cdetection channels, FL2 (509–552 nm), FL3 (565–605 nm),
FL4 (576-620 nm), FL5 (658–695 nm), and FL6 (>700 nm).
Signals for FITC, PE, Alexa Fluor 647, and Alexa Fluor 700
were collected through these detection channels. Voltages
of each light sensor module of each channel are optimized
for CTC detection (FSC: gain Low, SSC: 0.25 V, FL2:
0.35 V, FL3: 0.33 V, FL4:0.35 V, FL5: 0.48 V, and FL6:
0.35 V). On-chip Sort software version 24.1 (On-Chip Bio-
technologies) was used for signal acquisition. Data analysis
was performed using FlowJo software v7.6.5 (Tree Star,
Inc, Ashland, OR).
Enumeration and sorting procedures
Enumeration and sorting of cells were performed by On-
chip Sort according to the manufacturer’s instructions.
Briefly, the flow path was pre-washed with the 1 × Through
Path Plus (On-Chip Biotechnologies) and the On-chip sam-
ple buffer (1 × Through Path Plus with 1.5% polyvinylpyr-
rolidone, On-Chip Biotechnologies). Stained samples were
dissolved in 25 μL to 100 μL of On-chip sample buffer and
then a flow rate was up to 150 events/sec (about 1 μL/min:
1.8 kPa in the On-chip Sort setting). Total events were
approximately 1 × 105 to 106 events. The sorting time
required for all the samples was approximately 30 to
120 minutes depending on the final sample volume.
The sorted cells gated into the cytokeratin and/or vimen-


























s. (A) Image of the On-chip Sort cell sorter. (B) Image of the disposable
t sample/sheath reservoirs, which ensures that no fluids come into
oir by this shift of flow alone. A magnified view of the micro flow paths
mor cells gated as cytokeratin + and/or vimentin+/CD45− were sorted.
r cells (Tumor cell, TC; nuclei+/CK+ and/or vimentin+/CD45−) from the
D45+).
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escence microscope (Biorevo BZ-9000: Keyence, Osaka,
Japan) to confirm that the cells were nucleated (nuclear
stain-positive), cytokeratin and/or vimentin positive and
CD45 negative. All steps were carried out at room
temperature.
Whole genome amplification
Sorted cells were transferred from the collection reservoir
to a 200 μL polymerase chain reaction (PCR) tube and
rinsed the collection reservoir with sheath solution twice.
After centrification (600 x g for 10 min), the supernatant
was carefully aspirated to leave ~1 μL, which comprised
the starting volume of the whole genome amplification
(WGA) procedure. WGA was performed using the Ampli1
WGA kit (Silicon Biosystems, Bologna, Italy) following the
manufacturer’s protocol. The AMPure XP PCR Purification
Kit (Beckman Coulter, Beverly, MA) was used to clean up
the amplified DNA, and DNA concentrations were deter-
mined using a NanoDrop spectrophotometer (NanoDrop
Technologies, Waltham, MA, USA). Quality control checks
of the WGA product were performed using the Ampli1
QC Kit (Silicon Biosystems). Only samples positive for four
PCR products were considered to contain successfully
amplified genomic material suitable for mutation analysis.
Amplified DNA product of 2, 20 or 250 ng was subjected
to mutation analysis using quantitative real-time-PCR
(qPCR) amplification, pyrosequencing, or deep sequencing,
respectively.
Pyrosequencing
The amplification primers for mutations in EGFR, KRAS,
and BRAF are described in Additional file 1: Table S1. Py-
rosequencing PCR was performed following the manufac-
turer’s instructions.
Deep sequencing using the TruSeq Amplicon Cancer Panel
A total of 48 genes frequently mutated in cancer according
to the COSMIC database (Catalogue Of Somatic Mutations
In Cancer), were sequenced using a TruSeq Amplicon
Cancer Panel (TSACP; Illumina, San Diego, CA) following
the manufacturer’s instructions. Variant call analysis was
performed with Amplicon Viewer (Illumina). Coverage in-
formation was obtained using CLC genomics Workbench
6.0 (CLC Bio, Aarhus, Denmark).
Mutation analysis of lung tumor cells enriched with the
CellSearch profile kit.
To compare the cell capture performance of the On-chip
Sort platform versus the CellSearch platform (Veridex
LLC), nine tubes (three regular 5 mL blood collection
tubes containing EDTA) of blood were collected from a
healthy volunteer. H1975, A549 or H1755 tumor cells were
spiked into the 5 mL of blood to a final concentration of 10cells/mL. Two blood collection tubes (total of 10 mL blood)
were delivered to an independent medical laboratory
(Genetic Lab, Sapporo, Japan). There, tumor cell capture
was performed using the CellSearch profile kit (Veridex
LLC) or the On-chip Sort in parallel concurrently. Cap-
tured samples using the CellSearch profile kit were stored
in a CellSave Preservative Tube (Veridex LLC) and sent
back to our laboratory. After a single wash with T-buffer,
samples were stained as described above. Captured sam-
ples using the On-chip Sort were stored at 4°C until the
initiation of WGA in parallel with returned CellSearch
samples. Both samples were subjected to WGA concur-
rently, followed by mutation analysis.Gene copy number analysis for EGFR
qPCR amplification of the EGFR was performed on the
StepOnePlus Real-time PCR system (Applied Biosystems,
Foster City, CA) using SYBR Premix Ex Taq II (Tli RNase
H Plus; Takara Bio, Shiga, Japan). The amplification primers
used are described in Additional file 1: Table S1.Immunoblot analysis and immunofluorescence staining
Immunoblot analysis was as described previously [33].
Briefly, the cultured tumor cells were harvested and lysed
in lysis buffer (50 mM Tris-HCI, pH 7.4, 50 mM NaCI,
1% Nonidet P-40, 2 mM EDTA, 10 mM NaF, 2 mM so-
dium orthovanadate and protease inhibitor cocktail).
Whole cell lysate was electrophoresed on a 12% SDS-
PAGE gel, transferred to nitrocellulose membrane (Bio-Rad
Laboratories Inc., Hercules, CA) and immunoblotted with
the a the phospho-EGFR (Tyr1068, D7A5; Cell Signaling),
the EGFR (D38B1; Cell Signaling), or α-tubulin (YL1/2;
Millipore, Temecula, CA). The intensity of the bands was
quantified with ImageJ (Wayne Rasband, NIH, MD).
The cultured tumor cells were harvested and fixed.
After washing with T-buffer once, the cell pellet was dis-
solved in a staining solution containing the PE-conjugated
anti-CD326 (EpCAM) mAb 9C4 (1:25 dilution, BioLegend,
San Diego, CA) or Alexa Fluor 647-conjugated anti-EGFR
mAb D38B1 (Cell Signaling Technology). Samples were in-
cubated overnight at 4°C in the dark. Unbound antibodies
were removed via washing with 2 mL of T-buffer followed
by centrifugation. Flow cytometry was performed using the
On-chip Sort. Data analysis was performed using FlowJo
software v7.6.5.Statistical analysis
Prism software (GraphPad Software, Inc., La Jolla, CA)
was used for statistical analyses. Statistical significance of
difference was determined using the unpaired Student’s
t-test.
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Assay development for CTC detection and capture after
negative depletion enrichment
To capture CTCs in whole blood, we used a novel cell
sorter, On-chip Sort (Figure 1). Discrimination of CTCs
from the bulk of the blood cells was achieved by negative
enrichment using anti-human CD45 microbeads [30]. A
typical example for the full gating strategy is shown in
Figure 1C. Gating of the CTCs by On-chip Sort was car-
ried out using the CK-FITC staining vs. the vimentin-PE
staining density plot (Figure 1C, left). The lower limit of
the gate that discriminates CTC signals from WBCs
autofluorescence as well as from debris was determined
by several runs of non-spike experiments using healthy
donor control bloods (Additional file 2: Figure S1). The
CK+ and/or vimentin+ events were then subjected to
CD45 negative gating to distinguish tumor cells from
WBCs and/or debris. Tumor cell events that appeared
in the CD45-Alexa Fluor 700 vs. FL5 density plot (FL5 is a
detection channel adjacent to that for Alexa Fluor 700)
were easily distinguished from the WBCs and debris
population (Figure 1C, middle).
Immunofluorescence staining of the On-chip Sort sorted
cells identified these cells as nuclei, CK and/or vimentin-
positive and CD45-negative under the fluorescent micro-
scope, confirming these cells to be tumor cells. Tumor
cells were easily distinguished from WBC, which were
CD45-positive and CK-negative (Figure 1C, right). Five
healthy donor control samples were processed with
above settings (Additional file 2: Figure S1). On average
these samples have 1.2 ± 1.3 events in the CTC gate.
However no sorted tumor cells (CK+ and/or vimentin+,
CD45− cells) were observed.
Evaluation of captured tumor cells from spiked blood
samples
To assess the performance of our method, low numbers
(i.e., 5, 13, or 25 cells) of various non-small cell lung
tumor H1975, A549 or H1755 cells expressing varying
levels of EpCAM were spiked into 4 mL of normal blood,
and processed according to our protocol for tumor cell
isolation with the On-chip Sort system. As shown in
Figure 2A, H1975 cells displayed high EpCAM expres-
sion, whereas A549 cells exhibited partial EpCAM
expression. H1755 cells did not appear to express any
EpCAM.
Results of the sorting experiments are summarized
in Figure 2B and in Additional file 3: Table S2. Overall,
the mean percentages of cells detected into the gate as
shown in Figure 1C were 86.9% ± 8.6%, 84.7% ± 9.3%,
and 83.4% ± 12.4% for H1975, A549, and H1755 cells,
respectively (n = 9). These detection rates are compar-
able to those obtained in the previous report using
FISHMAN-R [30]. Captured cells into collecting reservoirwere confirmed to be tumor cells using microscopy of cell
morphology and positive CK and vimentin fluorescent
labeling, while contaminating cells were identified by cell
morphology and positive CD45 staining (Additional file 4:
Figure S2). Overall mean percentages of cells captured
were 68.5% ± 9.2%, 69.8% ± 9.9%, and 74.5% ± 12.7% for
H1975, A549, and H1755 cells, respectively. Observation
of CD45-positive cells under the fluorescent microscope
yielded a purity of captured tumor cells after cell isolation
with On-chip Sort of 78.4% ± 13.9%, 69.8% ± 18.5% and
70.4% ± 12.4% for H1975, A549, and H1755 cells,
respectively.
Regression analysis of the number of detected tumor
cells versus the number of expected tumor cells produced
a correlation coefficient (R2) of 0.9978, 0.9967 and 0.9965
for H1975, A549, and H1755 cells, respectively (Figure 2C,
blue line). The number of captured tumor cells was also
highly linear, with a correlation coefficient of R2 = 0.9928,
0.9985 or 0.9963 in H1975, A549, or H1755 cells, respect-
ively (Figure 2C, red line).
Validation of mutation detection methods
Prior to performing mutation analysis on tumor cells
captured with On-chip Sort, we tested whether WGA
products are usable for sequencing by pyrosequencing
and deep sequencing methods. The H1975 human lung
tumor cell line harboring known mutations in the EGFR
was used. Two single cells and two groups of ten cells
each were analyzed for the presence of two different
mutations in the EGFR; using both pyrosequencing and
deep sequencing subsequent to the WGA procedure.
Both mutations were reliably detected by pyrosequencing
even in single cells, as well as in both unamplified and
amplified H1975 genomic DNA carried out as a positive
control (Table 1). These EGFR mutations were not de-
tected in any of the amplified WBC samples carried out as
a negative control (Table 1).
Amplicon libraries were generated using the TSACP
followed by deep sequencing with an Illumina MiSeq
sequencer. Significant single nucleotide variants (occurring
in > 1% of DNA in the sample) were found in both the
small groups of cells as well as in the single cells with satis-
factory sequence coverage depth (Table 1). Similarly, A549
and H1755 human lung tumor cell lines harboring known
mutations in the KRAS and BRAF were also reliably called
with sufficient variant frequency when using small numbers
of cells as well as in single cells (Additional file 5: Table S3).
Analytical sensitivities of pyrosequencing and deep se-
quencing were analyzed by titration studies using normal
leukocyte and EGFR mutant H1975 cells. One or ten
mutant cells were mixed with wild-type cells (normal
leukocytes) in dilutions of 20, 5, and 1% of mutant cells.
All cell mixtures were subjected to WGA, followed by











































Detection   Capture      Purity








Detection   Capture      Purity
























Detection      
Capture   
0 10 20 30
Spiked cells (cells) Spiked cells (cells)
R² = 0.9985
Detection      
Capture   
0 10 20 30
R² = 0.9991
R² = 0.9963
Detection      
Capture   




H1975                                     A549                                      H1755
Spiked cells (cells)






Figure 2 Performance of On-chip Sort in a spike-in experiment. (A) Histograms of EpCAM expression in H1975, A549, and H1755 non-small
cell lung tumor cell lines. Fluorescence histograms of the isotype control (gray) and of the EpCAM antibody (red). (B) The mean
percent detection, capture and purity of 5, 13, and 25 tumor cells isolated following spiking into 4 mL of normal blood (n = 3). The number of
detected tumor cells was calculated using Flowjo software. The number of captured tumor cells was counted as the number of cells found in the
collection reservoir. Purity was calculated as the number of captured tumor cells divided by the number of captured tumor cells plus white blood
cells counted in the collection reservoir. (C) Linearity of tumor cell detection (blue lines) and capture (red lines) in spiking experiments. Error bars
represent S.D. of the mean. Data shown here are representative of two independent experiments for each assay.
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mutant cell dilutions of 1%, the deep sequencing method
was capable of detecting mutations in EGFR (Additional
file 6: Figure S3B), while pyrosequencing had a lower
detection limit of 10% (Additional file 6: Figure S3A).
Mutation analysis of captured tumor cells
To enable the mutation analysis of CTCs isolated with
On-chip Sort, the sorted lung tumor cell samples shown
in Figure 2 were analyzed for the presence of specific
mutations in each cell line using pyrosequencing anddeep sequencing. Variant frequencies were compared with
those of both unamplified and amplified H1975 genomic
DNA samples. Results of the mutation analysis of the cells
sorted for WGA and the purity of these samples are
summarized in Additional file 3: Table S2. All expected
mutations were reliably detected in all sorted samples
with sufficient coverage, with none detected in the amp-
lified WBC samples. These results suggest that even
where tumor cells were present at concentrations as low
as five cells per 4 mL of blood, they could be successfully
isolated using On-chip Sort, amplified genome DNA by
Table 1 Mutation analysis of single or small groups of tumor cells
Cells Template EGFR mutation Var. Freq.
by Pyro.
Var. Freq. by MiSeq Coverage min. = 10 ×
(212 amplicons)Var. Freq. Total read
H1975 Unamplified gDNA L858R (2573T>G) 75% 78.2% 13,070 100.0%
T790M (2369C>T) 74% 79.5% 11,044
H1975 Amplified gDNA L858R 73% 65.9% 372 96.7%
T790M 72% 75.2% 10,013
H1975 10 cells L858R 71% 88.8% 4,479 92.0%
T790M 79% 84.1% 27,539
H1975 10 cells L858R 73% 90.1% 601 93.5%
T790M 77% 80.9% 35,070
H1975 1 cell L858R 68% 77.1% 109 90.6%
T790M 79% 87.0% 31,312
H1975 1 cell L858R 69% 78.2% 368 80.2%
T790M 61% 63.8% 27,341
WBC from healthy donor 10 cells L858R 2% N/A 3,596 81.4%
T790M 0% N/A 18,497
WBC from healthy donor 1 cell L858R 3% N/A 56 88.7%
T790M 0% N/A 256
Footnote: Tumor cells or normal WBCs were fixed and stained followed by Ampli1 WGA. WGA products were sequenced using a pyrosequencer or the Illumina
MiSeq sequencer. Variant frequencies of two different mutations in the EGFR and the coverage distribution of WGA products using the TSACP are shown. Pyro.,
psyrosequence Var. Freq., variant frequency. Coverage min., coverage minimum.
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depth.
We further evaluated whether On-chip Sort was capable
of capturing very low number of tumor cells in blood. 4
mL blood samples containing one or two H1975 cells
were processed with On-chip Sort in 6 independent tests
(Additional file 7: Table S4). The results demonstrated a
sensitivity threshold for On-chip Sort platform detecting
close to one tumor cell per 4 mL of blood. In addition,
tumor cells were not detected from healthy donor blood
containing no tumor cells. Therefore, CTCs could be de-
tected and isolated form patients who have ≥1 CTCs per 4
mL of blood by the On-chip Sort platform and they could
be genotyped utilizing isolated CTCs.
We also found that EpCAM/CK double-negative
Hs578T cells spiked into healthy blood were successfully
isolated with On-chip Sort and profiled by mutation ana-
lysis (Additional file 8: Figure S4); the resulting mutation
profiles showed the expected genomic mutation in p53
known to be present in Hs578T. These results strongly
suggest that our CTC capture assay is advantageous for
capturing and characterizing both EpCAM-positive and
EpCAM-negative tumor cells.
Comparative analysis of On-chip sort versus the CellSearch
profile kit
We next performed a comparative analysis of On-chip
Sort versus the CellSearch profile kit in terms of mutationdetection of tumor cells spiked into blood samples. Cells
isolated using On-chip Sort or the CellSearch profile kit
were processed by WGA followed by mutation analysis
with pyrosequencing or deep sequencing. In On-chip
Sort-isolated samples, specific mutations in each tumor
cell line were reliably detected by both pyrosequencing
and deep sequencing (Figure 3, left). In CellSearch profile
kit-isolated samples however, specific mutations in H1975
cells expressing high EpCAM levels were detected by deep
sequencing only and not by pyrosequencing (Figure 3,
right). In both experiments, genomic DNA was suc-
cessfully amplified according to Ampli1 end-point PCR
criteria in all of the samples (Additional file 9: Figure S5).
Details of the mutation analysis are shown in Additional
file 10: Table S5. These data suggest that the On-chip
Sort assay provides superior sensitivity compared
with the CellSearch profile kit for subsequent mutation
detection.
Assessment of EGFR expression and copy number
amplification in captured tumor cells
Owing to the multichannel detection capability of the sys-
tem, EGFR expression levels on single CTCs are measur-
able and semi-quantifiable using an anti-EGFR antibody
in the FL5 channel of On-chip Sort. We first performed
experiments to demonstrate that EGFR immunostaining
on On-chip Sort could be correlated to EGFR expression
and gene amplification status as determined by western
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Figure 3 Head-to-head comparison of On-chip Sort with the CellSearch profile kit. Three tumor cell lines (H1975, A549 and H1755) expressing
varying levels of EpCAM were spiked into blood from a healthy donor (10 cells/mL). The samples were divided into three and then processed using
our On-chip Sort protocol as well as the CellSearch profile kit in parallel. Captured tumor cells were subjected to whole genome amplification followed
by mutation detection with both pyrosequencing and deep sequencing to detect specific mutations in each tumor cell. Variant frequencies detected
in the controls (gDNA and WBCs from a healthy donor) and experimental samples using pyrosequencing (A) or deep sequencing (B) are graphically
represented. The line represents the lower limit of detection of each method (10% for pyrosequencing and 1% for deep sequencing). Samples with 0%
variant frequency were assigned a value of 0.1 for plotting purposes. Data shown here are representative of two independent experiments for each assay.
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cell lines. To distinguish different levels of EGFR protein
expression and EGFR amplification, we used the EGFR-
over-expressing and/or EGFR-amplified cell lines H292,
A431, and HCC827 (Figure 4A, C). Very low-level EGFR-
expressing A549 cells with a single EGFR copy served as a
negative control (Figure 4A, C).
A549 cells were either weakly positive or negative,
whereas H292 cells also revealed moderate EGFR ex-
pression (Figure 4B). In A431 and HCC827 cells, strong
intensities of EGFR specific immunofluorescence were
observed (Figure 4B). These EGFR expression levels
correlated with those determined by immunoblot analysis
(Figure 4A). CTCs with moderate to strong intensities of
EGFR-specific immunofluorescence were assumed to be
EGFR-positive (H292, A431, and HC827), whereas CTCs
with negative or only weak intensities of EGFR-specific im-
munofluorescence were considered to be EGFR-negative
(A549) (Figure 4B).
EGFR expression levels determined using On-chip
Sort were consistent with the mean gene amplifications
determined by qPCR carried out on DNA extracts of the
corresponding cell lines (Figure 4C, black bars; A549,1.18-fold; H292, 1.69-fold; A431, 6.32-fold; HCC827,
25.37-fold). In line with these results, the analysis of
Ampli1 WGA products of genomic DNA (1 ng) and of
small numbers of cells including single cells, by EGFR
qPCR, revealed comparable mean values in the respective
cell lines (Figure 4C, grey bars). The mean gene amplifica-
tions of pure tumor cell samples (Figure 4C, grey bars)
and of those isolated by On-chip Sort (Figure 4C, blue
bars) were compared, and found to be reasonably similar
to that observed in the cell lines with strong expression
levels of EGFR (A431 and HC827; Figure 4C), whereas no
significant amplification was detected in H292, which ex-
presses moderate levels of EGFR (Figure 4C). The results of
these sorting experiments are summarized in Additional
file 11: Table S6.
Discussion
In this study, we have described a new approach for the
capture of rare tumor cells from immunomagnetically
pre-enriched blood samples. We provided proof-of-
principle demonstrating the feasibility of this approach
by using it to capture between one and ten tumor
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Figure 4 EGFR protein expression and EGFR amplification in tumor cells captured by On-ship Sort. (A, B) EGFR protein expression detected by
western blot (A), correlated with EGFR protein expression captured by On-chip Sort (B), for A549 low EGFR expression and no EGFR amplification,
H292 (moderate EGFR expression and amplification rate), A431 (strong EGFR expression and amplification rate), and HCC827 (strong EGFR expression
and large amplification rate) cell lines. (C) Comparison of EGFR amplification rates determined by qPCR with gDNA (black bar), and when usingAmpli1
WGA products (gray bars) including WGA of captured tumor cells (blue bars).
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deep sequencing.
In addition, we investigated the applicability of using
WGA products obtained from single CTCs with the
Ampli1 WGA kit. This WGA kit is the only commercially
available kit compatible with analysis of a single fixed cell.
Fixation is a crucial step for the staining of cytokeratin
and vimentin with fluorescent probes, and cytokeratin
positivity is included to gold standard criteria for CTC de-
tection. The WGA/sequencing procedure described in this
study was shown to be serviceable for the detection of a
broad range of somatic mutations in 48 cancer-related
genes in small numbers of cells, as well as in single cells
for the first time. A coverage depth of 10-fold was
achieved even for single cells at >90% of the nucleotide
positions. Next-generation sequencing-based diagnostics
may therefore hold the potential to provide clinically
relevant information using single CTCs.
Total CTC capture yield is important in genotyping as
well as in other applications, such as prognostic and
drug response measurements. The overall mean percent-
age of cells captured was 70.9% ± 10.6% (n = 27). The
percentage of cell loss attributed to the negative enrich-
ment procedure and sorting was about 20% and 10%,
respectively. The estimated capture limit of the number
of tumor cells captured by our system was 1.46 ± 0.22CTCs/4 mL blood. The cut-off number of CTC events
detected by the On-chip Sort method was 3 events/4 mL
blood (Additional file 2: Figure S1), suggesting that the
CTC capture efficiency of our system to detect mutation
might be sufficient for low CTC cohort numbers. In
fact, we were able to detect specific mutations from
blood samples containing one tumor cell.
In a low CTC cohort (<15 CTCs/7.5 mL), the rate of
successful subsequent WGA was reported to be 23.5%
(n = 34) after isolation using a conventional cell sorter
[20]. Cell loss during sample handling is a critical issue
in CTC isolation when using CellSearch [21,28]. Unlike
conventional cell sorters and CellSearch, the On-chip Sort
system employs a lossless whole volume sorting approach,
and as a result, displays 100% successful subsequent
WGA as well as mutation detection of spiked blood sam-
ples as low as five tumor cells in 4 mL blood (n = 9).
Purity of isolated CTCs is also crucial for obtaining
high sensitivity in mutation detection. The On-chip Sort
system isolated tumor cells at a purity of >60%, which is
sufficient for mutation detection using pyrosequencing
methods that have a sensitivity of approximately 10%.
When directly comparing mutation detection sensitivity
of our system with that of the CellSearch system and
profile kit, our system was observed to be significantly
more sensitive at low CTC numbers (<10 CTCs/mL).
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high EpCAM-expressing H1975 cells after our sorting
procedure was approximately 68%, which was sufficient
to call the mutations. However, in the same samples using
the CellSearch system, variant frequency was approxi-
mately 3%, which is insufficient for unambiguous variant
identification. These results suggest that our system dis-
plays superior purification efficiency for the detection of
mutations using the relatively low-sensitivity downstream
pyrosequencing method.
The use of EMT markers, e.g., vimentin, facilitated the
capture of EpCAM/CK double-negative tumor cell in
peripheral blood. The loss of EpCAM and/or CK in
tumor cells has been reported previously [34-39]. This
loss of epithelial cell properties is related to Epithelial-
to-Mesenchymal Transition (EMT). Our multicolor cell
sorting system allows us to capture a CTC-positive
marker and an EMT-related marker in parallel, suggesting
that a population of CTCs that has been missed by current
platforms might be able to capture and characterize using
our system. However, vimentin is also expressed on
mesenchymal stromal cells which normally circulate
[40]. Criteria for vimentin+ CTCs must be carefully defined
and evaluated in future clinical studies. We also consider
using other EMT-related makers such as N-cadherin or
twist in addition to vimentin staining to detect and cap-
ture CTCs which show mesenchymal phenotype [34,38].
Our multicolor cell sorting system equipped with multila-
ser has the potential to capture CTCs multiple EMT
markers. In addition to CTC markers, nuclear staining
positivity is regarded one of the golden standard criteria
to detect CTCs. It is important to incorporate nuclear
positivity in sorting gates to classify the events as CTCs
or not in the case of clinical samples. On-chip Sort can
be equipped with violet laser for detection of DAPI
staining. Further improvement of equipment is needed
to be a robust diagnostic tool for cancer patients.
While the use of Ampli1 technology has previously
been reported for PCR-based mutation analysis on single
cells [21,22], qPCR to determine copy number of single
cells using the Ampli1 kit has not yet been evaluated. In
our study, the mean gene amplification rates within various
tumor cells determined by qPCR on DNA extracts were
similar to those determined with Ampli1 WGA products
when using both DNA extracts as well as small numbers
of cells, including single cells. The amplification of the
EGFR could also be observed in captured samples, sug-
gesting our system might be capable for detecting gene
amplification on CTCs. Such analyses may assist in
predictive biomarker studies in cases where expression
levels of therapeutic targets may be predictive of thera-
peutic activity. For example, High EGFR expression of
tumor cells was shown to predict the benefit of anti-EGFR
therapy such as cetuximab [41].Evaluation of the clinical feasibility of phenotypic analysis
in captured CTCs by evaluating target gene expression
is still ongoing. The DETECT III trial assesses the use
of anti-HER2 treatments in HER2-negative breast can-
cer patients selected on the basis of CTC detection/
characterization [42], www.detect-studien.de. Results of
this trial will give an insight into the relevance of CTCs
in cancer treatment strategies. Our system has clear ad-
vantages over conventional systems when carrying out
longitudinal analyses of CTC dynamics in terms of protein
expression as well as of mutation status.
Conclusions
We have provided the first report on the performance of
the On-chip Sort system, a novel bench-top cell sorter that
allows the capture of low numbers of cells from human
blood samples. We have described the analytical charac-
teristics of the system and provided proof-of-principle
showing its feasibility in the capture and molecular
characterization of low numbers of tumor cells in blood.
Ongoing improvement of CTC enrichment processes from
whole blood and integration of single-cell technologies may
help to establish CTCs as a pivotal diagnostic tool for can-
cer patients towards enabling better-personalized therapies.
The data shown in this study imply the potential of the
On-chip Sort cell capture system and further evaluation
with clinical samples should be conducted.
Additional files
Additional file 1: Table S1. Primers used for pyrosequencing and
quantitative PCR (qPCR). *1: 5′ ends of the amplification primers were
biotinylated.
Additional file 2: Figure S1. Detection and sorting data of healthy
donor control samples. A typical example of healthy control samples
analyzed with On-chip Sort. On average five healthy donor control
samples have 1.2 ± 1.3 events (n = 5) in the CTC gate (CK+ and/or
vimentin+/CD45−), but no tumor cells were observe in the collecting
reservoir.
Additional file 3: Table S2. Details of mutation analysis of captured
cells. This table provides details of DNA from captured tumor cells shown
in Figure 2, which was amplified using Ampli1 WGA followed by
mutation detection with both a pyrosequencer and an Illumina MiSeq
sequencer. Variant frequencies of two different EGFR mutations and
single KRAS and BRAF mutations, as well as coverage distribution of WGA
products in the TruSeq Amplicon Cancer Panel are shown. Var. Freq.,
variant frequency. Coverage min., coverage minimum.
Additional file 4: Figure S2. Gallery of H1975 cells captured by
On-chip Sort in the collection reservoir. Captured cells are shown with
binding to fluorescently-labeled antibodies targeting cytokeratin,
vimentin, and CD45. The images allowed for identification of tumor cells
(arrow) and hematologic cells (arrowheads).
Additional file 5: Table S3. Mutation analysis of single or small groups
of A549 and H1755 cells. Tumor cells were fixed and stained followed by
Ampli1 WGA. WGA products were sequenced using a pyrosequencer or
an Illumina MiSeq sequencer. Variant frequency of KRAS or BRAF
mutations and WGA coverage distribution in the TruSeq Amplicon
Cancer Panel are shown. Var. Freq., variant frequency. Coverage min.,
coverage minimum.
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http://www.translational-medicine.com/content/12/1/143Additional file 6: Figure S3. Analytical sensitivity of mutation
detection. Dilutions of EGFR mutant H1975 cells spiked into healthy
donor WBCs were analyzed by both pyrosequencing and deep
sequencing for detection of T790M and L858R mutations. Variant
frequencies of EGFR mutations detected by the pyrosequencer (A) or
MiSeq sequencer (B) are graphically represented. The horizontal axis
shows the expected fraction of mutant EGFR cells. The vertical axis shows
the observed percentage of variant frequency. The variant frequencies of
the T790M mutation (diamonds) and of the L858R mutation (squares) are
indicated. Blue marks indicate dilutions of single H1975 cell into WBC
samples and green marks indicate dilutions of ten H1975 cells into WBC
samples. The line represents the lower limit of detection of the method
(10% for pyrosequencing and 1% for deep sequencing). Data shown here
are representative of two independent experiments for each assay.
Additional file 7: Table S4. Evaluation of sensitivity of On-chip Sort
platform for mutation detection. One or two cultured H1975 cells were
individually picked up using a micropipette under an inverted microscope,
spiked into 4 mL aliquots of healthy donor blood, and the resulting blood
samples were processed using the On-chip Sort platform in 6 separate tests.
Captured samples were analyzed for the presence of specific mutations in
each cell line using pyrosequencing.
Additional file 8: Figure S4. Capture and mutation profiling of
CK−/EpCAM − breast cancer cells. (A) Histograms of CK, EpCAM, and
vimentin expression in Hs578T cells. Fluorescence histograms of the
isotype control (gray) and of the EpCAM antibody (red). (B) CTC gates of
spiked Hs578T cells and gallery of Hs578T cells captured by On-chip Sort.
The images allowed for identification of Hs578T cells (arrow). (C) Details
of sorting results and mutation analysis using deep sequencing. DNA
from captured Hs578T cells was amplified using Ampli1 WGA followed by
mutation detection with an Illumina MiSeq sequencer. Variant frequencies
of p53 mutation and coverage distribution of WGA products in the TSACP
are shown. Var. Freq., variant frequency. Coverage min., coverage
minimum.
Additional file 9: Figure S5. Composite gel images of Ampli1 QC
end-point PCR products. Genomic DNA of experimental samples was
considered to be successfully amplified if all four of the control
genomic DNA sequences were detected. No amplification product was
obtained in either of the negative control samples (NTC and Buffer). All of
the captured samples obtained using either On-chip Sort or the CellSearch
Profile kit passed the Ampli1 amplification check. NTC, no template control;
gDNA, 1 ng of H1975 gDNA as a positive control for Ampli1 QC; Buffer,
negative control for WGA.
Additional file 10: Table S5. Details of mutation analysis of captured
tumor cells using On-chip Sort or the CellSearch profile kit. This table
provides details of the captured sample in Figure 3 that were subjected to
mutation analysis. DNA from captured tumor cells were amplified using
Ampli1 WGA followed by mutation detection using both the pyrosequencer
and the Illumina MiSeq sequencer. Variant frequencies of two different EGFR
mutations, single KRAS and BRAF mutations, and coverage distribution of
WGA products in the TruSeq Amplicon Cancer Panel are shown. Var. Freq.,
variant frequency. Coverage min., coverage minimum.
Additional file 11: Table S6. Capture efficiencies and purity of tumor
cells spiked into 4 mL of normal blood. This table provides details of the
captured samples show in Figure 4 that were subjected to copy number
analysis. The number of captured tumor cells was counted as the
number of tumor cells found in the collection reservoir. Purity was
calculated as the number of captured tumor cells divided by the number
of captured tumor cells plus the number of white blood cells counted in
the collection reservoir (n = 2).
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